EDP-938 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EDP-938 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EDP-938 overview
EP-938 is under development for the treatment of respiratory syncytial virus (RSV-A and RSV-B) infections. The drug candidate is administered through oral route and it is a new chemical entity, a non-fusion inhibitor that targets Nucleocapsid protein (N protein).
Enanta Pharmaceuticals overview
Enanta Pharmaceuticals (Enanta) is a clinical-stage biotechnology company that develops small molecule drugs for viral infections. The company’s pipeline includes glecaprevir, EDP-514, EDP-938, EDP-323, EDP-235, EDP-305, EDP – 297.h Its pipeline candidates treat hepatitis C virus (HCV), Hepatitis B virus (HBV), respiratory syncytial virus (RSV), COVID-19 and non-alcoholic steatohepatitis (NASH). Its brands include Mavyret and Vieira pak. The company works in partnership with the National Institute of Allergy and Infectious Diseases, AbbVie Inc, Novartis, Shionogi Inc to discover two protease inhibitor compounds. Enanta is headquartered in Watertown, Massachusetts, the US.
For a complete picture of EDP-938’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
